S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
A 'soft landing' or a recession? How each one might affect America's households and businesses
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
A 'soft landing' or a recession? How each one might affect America's households and businesses
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
A 'soft landing' or a recession? How each one might affect America's households and businesses
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
All the trading advice you’ve ever received boils down to this (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
All the trading advice you’ve ever received boils down to this (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
A 'soft landing' or a recession? How each one might affect America's households and businesses

Kura Oncology Stock Price, News & Analysis (NASDAQ:KURA)

$10.81
-0.49 (-4.34%)
(As of 12/8/2023 ET)
Compare
Today's Range
$10.40
$11.44
50-Day Range
$7.58
$11.30
52-Week Range
$7.41
$15.50
Volume
1.36 million shs
Average Volume
685,951 shs
Market Capitalization
$802.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.31

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
152.7% Upside
$27.31 Price Target
Short Interest
Bearish
16.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
-0.08mentions of Kura Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.09) to ($2.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

849th out of 954 stocks

Biotechnology Industry

94th out of 111 stocks


KURA stock logo

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

KURA Stock Price History

KURA Stock News Headlines

Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Scotiabank Reaffirms Their Hold Rating on Kura Oncology (KURA)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
14 Best Cancer Stocks To Buy Now
What Makes Kura Oncology (KURA) a New Buy Stock
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.31
High Stock Price Target
$37.00
Low Stock Price Target
$10.50
Potential Upside/Downside
+152.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-135,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.28 per share

Miscellaneous

Free Float
70,113,000
Market Cap
$802.88 million
Optionable
Optionable
Beta
0.68
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price target for 2024?

8 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $27.31 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2023?

Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA shares have decreased by 12.9% and is now trading at $10.81.
View the best growth stocks for 2023 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our KURA earnings forecast
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.06.

What ETF holds Kura Oncology's stock ?

Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (5.89%), Armistice Capital LLC (3.01%), Affinity Asset Advisors LLC (1.15%), Northern Trust Corp (0.95%), Acuta Capital Partners LLC (0.95%) and Charles Schwab Investment Management Inc. (0.76%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Thomas James Doyle and Thomas Malley.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -